BaseMap ABE Launched for Off-Target Characterization in Base Editing Therapeutic Development

Broken String Biosciences, based in Cambridge, U.K., has unveiled BaseMap ABE, a tool designed for off-target characterization in base editing therapeutic development. This platform relies on the company's INDUCE-seq® technology to facilitate precise adenine base editing, an innovative method that permits targeted single-base modifications in the genome.

As the use of ABE expands in therapeutic applications, researchers are in need of consistent and reliable methods to systematically identify and analyze any unintended off-target effects, stated Terry Pizzie, the CEO of Broken String Biosciences. According to Pizzie, unlike prediction methods, BaseMap ABE produces comprehensive genome-wide data directly from biologically relevant cells, offering researchers a clear picture of the editor's specificity under conditions that mirror real-life scenarios.

He further explained that this platform enables swift, unbiased detection of off-target events, as well as the generation of standardized and reliable data to aid in optimizing guides, selecting editors, and making preclinical decisions. This launch marks the initial phase of Broken String Biosciences' expansion into base editing applications.

The company plans to engage in close collaboration with researchers who are working on genome editing therapies through its Early Access Program. This partnership aims to provide early adopters with valuable experience and to gather feedback that can guide future product development efforts.